

532.297
10/532297

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037261 A1

(51) International Patent Classification⁷: **A61K 31/506**,
45/06, A61P 9/12

Alexander [US/US]; 1127 Philip Street, New Orleans, LA
70130 (US).

(21) International Application Number:
PCT/IB2003/004671

(74) Agents: **HOXIE**, Thomas et al.; Novartis AG, Corporate
Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 20 October 2003 (20.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ,
TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:
60/421,318 25 October 2002 (25.10.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **THE
ADMINISTRATORS OF THE TULANE EDUCA-
TIONAL FUND** [US/US]; 1430 Tulane Avenue, SL-13,
New Orleans, LA 70112 (US).


Published:
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **LASKY**, Joseph,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF N-5'-4-(4-METHYLPIPERAZIOMETHYL)-BENZOYLAMIDO-2-METHYLPHENYL-4-(3-PYRIDYL)2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION



(57) Abstract: The present invention pertains to the use of 4-(4-methylpiperazin-1-yl-methyl)-N[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of pulmonary hypertension.

(I)

WO 2004/037261 A1